MIP-4/CCL18 蛋白, Human

MIP-4/CCL18 Protein, Human is a CC chemokine ligand that binds to PITPNM3, GPR30 and CCR8 receptors and also acts as a neutral CCR3 antagonist mediating inflammation, autoimmunity and carcinogenesis. MIP-4/CCL18 Protein, Human is a recombinant human MIP-4/CCL18 (A21-A89) protein expressed by E. coli^[1][2].

CCL18，也称为巨噬细胞炎症蛋白 4 (MIP-4)、肺和活化调节趋化因子 (PARC)、树突状细胞 (DC) 趋化因子 1 (DC-CK1) 和替代巨噬细胞活化相关 CC 趋化因子-1（ AMAC-1) 是 CC 趋化因子家族的一种小细胞因子。CCL18位于人类基因中的17号染色体上，与CCL3具有最高的氨基酸一致性（65%），编码一个89个氨基酸长的蛋白质，在N'端有一个20个氨基酸长的肽信号序列，信号其分泌和在内质网中裂解成 69 个氨基酸的长成熟蛋白^[1]。CCL18主要由先天免疫系统的抗原呈递细胞产生，包括树突状细胞、单核细胞和巨噬细胞，但T细胞和B细胞中不产生。在巨噬细胞中，CCL18 由 Th2 细胞因子 IL-4 和 IL-13 诱导，这些细胞因子编程巨噬细胞分化为 AAM，从而有助于急性炎症反应的愈合阶段以及慢性炎症疾病中的组织重塑和纤维化。CCL18 可以结合PITPNM3、GPR30 和 CCR8 受体，其中 CCL18 与 CCR8 的结合诱导 Th2 细胞的趋化性。此外，CCL18还可以作为中性CCR3拮抗剂，参与炎症反应。研究表明，在活动性嗜酸性粒细胞炎症期间，CCL18 及其受体 CCR8 在患病人体组织中共表达。与此同时，CCL18 的产生增强已在多种疾病中得到证实，包括各种恶性肿瘤和炎症性关节、肺部和皮肤疾病^[2]。

CCL18 (20 ng/mL, 12-48 h) promotes HUVEC angiogenesis and enhances HUVEC migration without enhancing proliferation, while blocking the effect of CCL18 with a neutralizing anti-CCL18(10 μg/mL) antibody inhibits tumor-associated macrophages(TAM)-dependent HUVEC migration in a concentration-dependent manner^[3].
CCL18 (50 or 100 ng/mL, 36 h) results in significantly lower E-cadherin expression levels and higher MMP-2 and VEGF-C expression levels compared to controls, also can promote migration and invasion via CCR8 in bladder cancer cells^[4].

1.Full biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration of 1.0-10 ng/mL.
2.Measured by its ability to inhibit Eotaxin-induced chemotaxis of BaF3 mouse pro-B cells transfected with human CCR3. The ED₅₀ for this effect is 2.142 μg/mL.

Human

E. coli

Tag Free

P55774 (A21-A89)

6362  [NCBI]

AQVGTNKELCCLVYTSWQIPQKFIVDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA

Approximately 7.9-9 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, pH 7.4, 100 mM NaCl or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. K Hieshima, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol. 1997 Aug 1;159(3):1140-9.  [Content Brief]

  [2]. Schutyser E, et al. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005 Jul;78(1):14-26.  [Content Brief]

  [3]. Sabina A Islam, et al. Identification of human CCR8 as a CCL18 receptor. J Exp Med. 2013 Sep 23;210(10):1889-98.  [Content Brief]

  [4]. Ling Lin, et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget. 2015 Oct 27;6(33):34758-73.  [Content Brief]

  [5]. Xiaoqiang Liu, et al. CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells. Mol Med Rep. 2019 Mar;19(3):1678-1686.  [Content Brief]